Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease

M. A. Jacobson; J. Gallant; L. H. Wang; D. Coakley; S. Weller; D. Gary; L. Squires; M. L. Smiley; M. R. Blum; J. Feinberg

Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease

M. A. Jacobson, J. Gallant, L. H. Wang, D. Coakley, S. Weller, D. Gary, L. Squires, M. L. Smiley, M. R. Blum, J. Feinberg

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

Valaciclovir, the L-valyl ester of acyclovir, is rapidly and extensively converted in humans to acyclovir after oral administration by first-pass metabolism. A phase I study was conducted in two cohorts of volunteers with advanced human immunodeficiency virus (HIV) disease (absolute CD4 lymphocyte count of

Original language	English (US)
Pages (from-to)	1534-1540
Number of pages	7
Journal	Antimicrobial Agents and Chemotherapy
Volume	38
Issue number	7
State	Published - 1994
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)

Cite this

@article{8b901a4fa4ad46bebe41c9e088688743,

title = "Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease",

abstract = "Valaciclovir, the L-valyl ester of acyclovir, is rapidly and extensively converted in humans to acyclovir after oral administration by first-pass metabolism. A phase I study was conducted in two cohorts of volunteers with advanced human immunodeficiency virus (HIV) disease (absolute CD4 lymphocyte count of ",

author = "Jacobson, {M. A.} and J. Gallant and Wang, {L. H.} and D. Coakley and S. Weller and D. Gary and L. Squires and Smiley, {M. L.} and Blum, {M. R.} and J. Feinberg",

year = "1994",

language = "English (US)",

volume = "38",

pages = "1534--1540",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

TY - JOUR

T1 - Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease

AU - Jacobson, M. A.

AU - Gallant, J.

AU - Wang, L. H.

AU - Coakley, D.

AU - Weller, S.

AU - Gary, D.

AU - Squires, L.

AU - Smiley, M. L.

AU - Blum, M. R.

AU - Feinberg, J.

PY - 1994

Y1 - 1994

N2 - Valaciclovir, the L-valyl ester of acyclovir, is rapidly and extensively converted in humans to acyclovir after oral administration by first-pass metabolism. A phase I study was conducted in two cohorts of volunteers with advanced human immunodeficiency virus (HIV) disease (absolute CD4 lymphocyte count of

AB - Valaciclovir, the L-valyl ester of acyclovir, is rapidly and extensively converted in humans to acyclovir after oral administration by first-pass metabolism. A phase I study was conducted in two cohorts of volunteers with advanced human immunodeficiency virus (HIV) disease (absolute CD4 lymphocyte count of

UR - http://www.scopus.com/inward/record.url?scp=0028260966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028260966&partnerID=8YFLogxK

M3 - Article

C2 - 7979285

AN - SCOPUS:0028260966

SN - 0066-4804

VL - 38

SP - 1534

EP - 1540

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 7

ER -

Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this